Close

Top Stories

The Active & Intelligent Packaging Industry Association, AIPIA, is delighted to announce that GlaxoSmithKline will be hosting this year’s AIPIA Congress Challenge.

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced its Russia compliance solution, providing companies with the ability to meet requirements for serialization, traceability, and compliance reporting in the Russian market, in advance of the country’s December 2019 enforcement deadline.

Powder containment and aseptic transfer valve specialist, ChargePoint Technology has appointed Andrew McCreadie as their new business development manager for Europe, Middle East, India and Africa (EMEIA).

Codexis, Inc , a leading protein engineering company, announces the appointment of Hicham Alaoui, Ph.D. to the newly created position of Vice President, Biotherapeutics Research & Development.

STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, announces that its Active Pharmaceutical Ingredient (API) manufacturing facility at Jinshan (Shanghai, China) has successfully passed its fourth inspection from the U.S. FDA with no Form 483s issued. The site previously passed three FDA inspections in 2013, 2014 and 2016.

Dr. Kathleen Anne Welsh-Bohmer, a specialist in Alzheimer’s Disease (AD) research, has joined the scientific leadership team at NeuroCog Trials (NCT) as the Vice President of Neurodegenerative Disorders.

The filling and closing machine AFG 5000 from Bosch Packaging Technology recently received the internationally renowned “Red Dot Award” from the Design Zentrum Nordrhein-Westfalen in the category product design.

The Institut Pasteur officially unveiled its new Thermo Scientific Krios Cryo-TEM electron microscope at an event in Paris, France.

Access to good biomarkers is crucial in selecting the right patient groups for future clinical trials, thus increasing the likelihood that the study will succeed and, in the long run, allowing the development of effective treatment to combat severe cancers.

A report from bioLIVE – the new UBM biomanufacturing and bioprocessing event taking place in Madrid (October 9-11, 2018) – has collected findings from a panel of experts to identify a number of potential applications of small molecule expertise that should be applied to the biologics industry.

Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neuro degenerative therapeutics, announced that it has been awarded $3.4 million from the National Institute of NINDS in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

UBM India, India's leading B2B exhibition organizer, is all set to bring in the third edition of the widely appreciated India Pharma Week (IPW), a week-long celebration packed with avant-garde events from December 10-14, 2018 alongside its flagship expo CPhI & P-MEC India (December 12-14, 2018) to North India.

LANXESS is raising its prices for Durethan A (polyamide 6.6) compounds in Europe, Middle East and Africa by EUR 0.60/kg with immediate effect.

Progressive Care Inc. , a personalized healthcare services and technology company, launched a new program designed to educate patients and providers on treatment alternatives to opioids available through the company.

According to ISO annual survey published in November 2017, 1,025,761 certificates were issued based on ISO 9001:2008 but only 80,596 certificates based on the new ISO 9001:2015 during 2016.

SternMaid issued an invitation to an international symposium with scientific lectures, product tasting and a tour of the production facility.

As a groundbreaking innovation, Company EvCon - member of Cevital group - is exhibiting the UPWaterSystem on the process technology trade show ACHEMA 2018 in Frankfurt. The technology was developed in Germany and is based on the Vacuum Membrane Distillation Process.

In a recent study1 , scientists confirmed the ability of Omyapharm® to formulate orally disintegrating tablets (ODTs) with enhanced mouthfeel and examined their acceptability among healthy volunteers.

How can digital trends be used purposefully in regards to the application of injection systems? That is the key question being addressed by Vetter’s Open Innovation Challenge.

CRF Health, the leading provider of patient-centered eSource technology solutions for the life sciences industry, announced that it will host a series of interactive workshops and speaker sessions at DIA’s 2018 Global Annual Meeting, June 24-28, Boston, MA.

HIMSS Asia Pacific and Elsevier, the global information analytics company specializing in science and health, are proud to announce the call for submissions for the 6th Annual Asia Pacific (APAC) HIMSS-Elsevier Digital Healthcare Award 2018.

A survey of 229 life science professionals from The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, has found the majority (72%) believe their sector is lagging behind other industries in its development of AI.

Wize Pharma, Inc , a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced that it has signed an exclusive distribution agreement with HPGC Medical Co., Ltd.

Global benchmarking company STEM Healthcare (STEM) is pleased to announce the appointment of Tim Missey as US President effective June 4th 2018.

Moisture determination can benefit product quality at many stages of production including goods-in, in-process control, and final QC. Traditionally, oven-drying produced the reference method for these analyses.

Dr. Matthias L. Wolfgruber (64) is the new Chairman of the Supervisory Board of LANXESS AG.

DSCSA( Drug Supply chain Security Act):The bill was signed by President Obama on 27th November, 2013 to amend the federal Food, Drug and Cosmetic Act to grant the FDA with more authority to regulate and monitor the manufacturing of compounded drugs.

Bayer announced that the latest research across its growing oncology portfolio will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place June 1-5 in Chicago.

Celgene Corporation plans to present at four upcoming investor conferences and events where Celgene management will provide an overview of the Company.

Astellas Pharma Inc announced hat a wide selection of abstracts highlighting the Company's diverse oncology portfolio across a broad range of cancers have been accepted for oral and poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5 in Chicago.

Wieland Thermal Solutions at the ACHEMA 2018, hall 6.1, booth C4.Ulm, May 23rd - From 11th to 15th June the Achema, the World Forum and Leading Show for the Process Industries, will take place in Frankfurt.

Amgen announced a groundbreaking collaboration with the National Cancer Institute (NCI), the FCC Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Center and the University of California, San Diego (UCSD) Design Lab to support the improvement of cancer outcomes.

Working in a laboratory, especially when handling toxic substances, requires general precautions. Users should be properly trained and abide by certain rules to ensure safety for the entire lab.

USP compliance is essential for international pharmaceutical manufacturers and suppliers, particularly if they sell to the North American market. However, strict USP guidelines have also been adopted around the world.

Boehringer Ingelheim, the world’s second largest animal health company, has been boosting its investment in China by expanding the Asian Veterinary Research & Development (R&D) Center to enhance its research and innovation capacity.

Mitsubishi Tanabe Pharma Corporation MTPC announced that Canagliflozin received the Technology Award Grand Prize at the 50th JCIA Awards.

CPhI & P-MEC China (#CPhIChina) – organized by UBM and UBM SINEXPO – takes place at the Shanghai New International Expo Center (SNIEC) on 20-22nd June 2018.

GlaxoSmithKline plc (GSK) will present extensive data from across its respiratory portfolio, pipeline and early phase research programmes at the American Thoracic Society (ATS) conference in San Diego, USA, 19-23 May 2018.

TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced the latest keynote speakers for its upcoming FutureLink Munich conference to be held June 5-7, 2018.

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced the launch of a new online customer portal designed to enable customers to better monitor project progress and track communications.

Family-owned pharmaceutical company Boehringer Ingelheim presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease Boundaries’, at its global headquarters in Ingelheim, Germany.

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, and global biotechnology leader CSL Limited announced an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor (C1-INH) proteins for Hereditary Angioedema (HAE) and other potential indications using CEVEC's proprietary CAP(R)Go technology.

On the occasion of its 20th anniversary, the Swiss Biotech Association launches Swiss Biotech Success Stories in recognition of the industry’s many accomplishments.

Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease.

Bracket, a leading clinical trial technology and specialty services provider, has won the Best Patient-Focused Technological Development award at the Clinical and Research Excellence (CARE) Awards.

STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), announces that it has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center.

Vetter, a global leader in prefilled drug-delivery systems was paid a special visits at its Ravensburg, Germany facilities by Illinois Governor, Bruce Rauner.

CRF Health, the leading provider of patient-centered eSource for the life sciences industry, announced that its TrialMax Touch® and TrialMax Slate® solutions have been selected by a Global Category Japanese Pharmaceutical company for a significant pain trial.

Drug Safety 2018 aims to discuss the latest findings and current thinking on pharmacovigilance. Importantly, it will address the newest regulatory updates and interpretations of them, including the impact of the vital and much awaited Clinical Trial Regulations.

SMi are delighted to have our Chairman, Speaker and Workshop Host, Justin Mason-Home, Director, HPAPI Project Services Limited, onto the speaker panel for HPAPI 2018!

AstraZeneca presented new post-progression outcomes data from an exploratory analysis of the global Phase III FLAURA trial, which assessed the efficacy and safety of Tagrisso (osimertinib) as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Novartis announced a new post hoc analysis of the pivotal Phase III heart failure study, PARADIGM-HF, demonstrating that treatment with Entresto® (sacubitril/valsartan) helped to preserve kidney function, as assessed by estimated glomerular filtration rate (eGFR), in patients with heart failure with reduced ejection fraction (HFrEF).1

Hercules Pharmaceuticals, a Dutch biopharmaceutical company developing innovative anti-cancer drugs will present a poster, Poster LB-128, at the AACR meeting in Chicago on Monday April 16, 2018, from 8:00am-12:00pm, Poster section 45.

Powder containment and aseptic transfer valve specialist ChargePoint Technology, has appointed two new area managers to support the increased demand for its containment technologies and solutions throughout the US.

CPhI South East Asia organised by UBM has announced that from 2019 onwards it will alternate its annual location between the region’s two largest pharma economies, Indonesia and Thailand.

TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced the latest industry speakers confirmed for FutureLink Munich, which will occur June 6-7, 2018 at the Sheraton Munich Arabellapark Hotel.

Boehringer Ingelheim announced data from the landmark 52-week DYNAGITO® trial which show that in people with COPD (chronic obstructive pulmonary disease), Spiolto®Respimat® (tiotropium/olodaterol 5/5µg) lowers the rate of moderate-to-severe exacerbations compared with Spiriva® Respimat® (tiotropium).

METTLER TOLEDO is pleased to present a new poster entitled “10 Practical Tips for Correct Test Weight Handling” This free poster illustrates actions you can take to protect the accuracy of your test weights.

Aptar Pharma, a leading drug delivery systems provider, is proud to announce its leading role in the organization of the forthcoming 7th Innovative Drug Delivery Solutions Symposium (IDDS). The biennial conference is to be held this year at the SORL Hotel Hangzhou, Hangzhou, Chinafrom March 28-30, 2018.

Aptar Pharma, a leading global solution provider of innovative drug delivery systems, is pleased to be a Platinum Sponsor at RDD 2018, taking place from April 22 to April 26 at the JW Marriott Starr Pass Resort and Spa,Tucson, Arizona.

Vetter has won the 2018 ISPE Facility of the Year Award (FOYA) in the Facility of the Future category for its Center for Visual Inspection and Logistics.

Orchard Therapeutics, a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announced two key additions to its executive leadership team, appointing Jason Meyenburg as chief commercial officer and John Ilett as general counsel & company secretary.

New data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIATM-AF, were presented at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA).1,2 The registry examined two-year safety and effectiveness outcomes of nearly 5,000 AF patients treated with dabigatran (marketed as Pradaxa®). Results of the completed Phase II of GLORIATM-AF,1 presented during the ‘Late-breaking science – Registries’ session, showed low rates of major bleeding (0.97%) and stroke (0.65%). These findings confirm the sustained safety and effectiveness of dabigatran and are highly consistent with the long-term safety profile observed in other real-world evidence, as well as in randomised clinical trials.

“Long-term, ‘real-world’ data are important to cardiologists as they help build a bigger picture of how an antithrombotic medication works in daily clinical practice,” commented Gregory Y H Lip, MD, Co-Chair of the GLORIATM-AF Steering Committee. “The results from the second phase of GLORIATM-AF underline the safety and effectiveness of dabigatran, which is reassuring for physicians treating patients with atrial fibrillation.”

In an additional analysis from GLORIATM-AF2 the safety of uninterrupted dabigatran for patients undergoing cardiovascular (CV) interventions was evaluated. The rates of major bleeding and stroke/ systemic embolism were very low, i.e. one major bleed and one systemic embolic event occurred in 412 CV interventions that were performed with uninterrupted dabigatran.

“From the first clinical trials such as RE-LY® and RELY-ABLE®, through to numerous real-world studies, both supported by and independent from Boehringer Ingelheim, we get an absolute, consistent picture of the favorable safety of dabigatran,” commented Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Recent clinical trials in specific settings like RE-CIRCUITTM,3 with dabigatran in AF patients undergoing cardio ablation, again demonstrated the superior safety of Pradaxa® compared to standard-of-care. The prospective, long-term data for dabigatran from GLORIATM-AF now add one further piece to complete this picture with profound real-world evidence.”

AF is the most common cardiac rhythm disorder worldwide, with numbers expected to rise in the coming years.4 Overall, people diagnosed with AF have a five-fold increased risk of stroke,5 which occurs when a blood clot blocks a vessel in the brain. Each year three million patients suffer AF-related strokes.6,7New data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIATM-AF, were presented at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA).1,2 The registry examined two-year safety and effectiveness outcomes of nearly 5,000 AF patients treated with dabigatran (marketed as Pradaxa®). Results of the completed Phase II of GLORIATM-AF,1 presented during the ‘Late-breaking science – Registries’ session, showed low rates of major bleeding (0.97%) and stroke (0.65%). These findings confirm the sustained safety and effectiveness of dabigatran and are highly consistent with the long-term safety profile observed in other real-world evidence, as well as in randomised clinical trials.

“Long-term, ‘real-world’ data are important to cardiologists as they help build a bigger picture of how an antithrombotic medication works in daily clinical practice,” commented Gregory Y H Lip, MD, Co-Chair of the GLORIATM-AF Steering Committee. “The results from the second phase of GLORIATM-AF underline the safety and effectiveness of dabigatran, which is reassuring for physicians treating patients with atrial fibrillation.”

In an additional analysis from GLORIATM-AF2 the safety of uninterrupted dabigatran for patients undergoing cardiovascular (CV) interventions was evaluated. The rates of major bleeding and stroke/ systemic embolism were very low, i.e. one major bleed and one systemic embolic event occurred in 412 CV interventions that were performed with uninterrupted dabigatran.

“From the first clinical trials such as RE-LY® and RELY-ABLE®, through to numerous real-world studies, both supported by and independent from Boehringer Ingelheim, we get an absolute, consistent picture of the favorable safety of dabigatran,” commented Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Recent clinical trials in specific settings like RE-CIRCUITTM,3 with dabigatran in AF patients undergoing cardio ablation, again demonstrated the superior safety of Pradaxa® compared to standard-of-care. The prospective, long-term data for dabigatran from GLORIATM-AF now add one further piece to complete this picture with profound real-world evidence.”

AF is the most common cardiac rhythm disorder worldwide, with numbers expected to rise in the coming years.4 Overall, people diagnosed with AF have a five-fold increased risk of stroke,5 which occurs when a blood clot blocks a vessel in the brain. Each year three million patients suffer AF-related strokes.

SMi are delighted to present the 2nd annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) conference being held at Holiday Inn, Kensington Forum, London, on the 21st – 22nd May 2018.

The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, is calling upon the industry to support the ‘Lab of the Future’ (LoTF) through greater collaboration.

Increased international generic API companies and suppliers are reported at next month’s CPhI Japan 2018, traditionally an innovative drug focussed market, due to recent changes in the country.

Clinerion’s Board of Directors announces the appointment of Ian Rentsch as new CEO of the company, effective April 1, 2018.

Gilead Sciences, Inc. announced that Norbert Bischofberger, PhD, has decided to step down from his role as Executive Vice President, Research and Development and Chief Scientific Officer, effective at the end of April 2018.

Novartis announced changes to its senior leadership team to support the implementation of its strategic priorities. Bertrand Bodson, Chief Digital Officer, Steffen Lang, Global Head Novartis Technical Operations, and Shannon Klinger, Chief Ethics, Risk and Compliance Officer, have been appointed to the Executive Committee of Novartis (ECN).

Recipharm, the contract development and manufacturing organisation (CDMO), announces its new Blow-fill-seal machinery is now operational following a substantial investment last year at its facility in Kaysersberg, France.

An expert judging panel of IndustryWeek editors and advisors has selected the Thermo Fisher Scientific Auburn manufacturing site in Alabama as one of seven 2017 Best Plant winners.

Recipharm has announced that its 2017 International Environmental Award will be presented to Karen Kidd, Professor in Biology, and Geography & Earth Sciences at McMaster University in Hamilton, Ontario and Jarislowsky Chair in Environment and Health.

Powder containment and aseptic transfer valve specialist ChargePoint Technology has obtained the highest level of quality accreditation at its Liverpool, UK facility, to enable future product development for use in hazardous environments.

The pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India.

The Regulatory Affairs Professionals Society (RAPS) continues its support of medical device professionals in Europe with the launch of a workshop focused on 510(k) premarket submissions to the US Food and Drug Administration (FDA).

A small specialist British engineering company called Priorclave celebrates 30 years in the design, manufacture and world-wide supply of an extensive range of laboratory and research grade autoclaves.

Lonza has announced a panel of top endotoxin experts to present at the 4th Global Endotoxin Testing Summit from 12-14 June 2018, in Annapolis, MD (USA).

Haverford Trust Co. lifted its position in shares of Eli Lilly and Co by 16.3% during the fourth quarter, according to the company in its most recent filing with the SEC.

Bristol-Myers Squibb Company announced that its Board of Directors has elected José Baselga, M.D., Ph.D., to the Board, effective March 1, 2018. Dr. Baselga will serve as a member of Science & Technology Committee of the Board of Directors.

Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting (AGM). A total of 1,731 shareholders were present at the meeting held in Basel, representing approximately 62.6% of the issued shares of Novartis.

Laboratory scientists across the globe can now benefit from a software system that helps them manage the entire lab, designed to support process adherence, data integrity and complete regulatory compliance.

A month has gone by since the last earnings report for AbbVie Inc. ABBV . Shares have added about 9.7% in that time frame, outperforming the market.

According to the study published in the Journal of Clinical Endocrinology and Metabolism, the presence of gut flora may be healthy for some people, while it may increase the risk of obesity in others.

On average its rare disease patients – around half of whom are children – have to wait for five years before they receive the correct diagnosis for their condition.

Merck & Co. fell after a federal judge tossed a record $2.54 billion verdict it had won against Gilead Sciences Inc. over a hepatitis treatment.

GPs and general practices are under serious pressure through increasing workloads not least due to more complex cases and the health challenges of an aging population.

In December, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) started a review of the treatment for abnormal bleeding in women with uterine fibroids after four cases of serious liver injury - three resulting in a liver transplant - were reported among users of the drug.

Richard Wolf, answering strong global demand for its high-performance endoscopic technology services, today announced plans to expand in Southeast Asia by opening its 15th subsidiary to be located at the heart of Southeast Asia – Singapore.

Bayer and Loxo Oncology, Inc., , a biopharmaceutical company from Stamford announced the publication in The New England Journal of Medicine (NEJM) of larotrectinib data for the treatment of pediatric and adult patients whose tumors harbor Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusions.

Envigo, a leading provider of nonclinical contract research services and research models, announced the appointment of Lynn Lewis to the position of Senior Vice President, Global Sales.

Contract development and manufacturing organisation (CDMO) Saneca Pharma has announced the appointment of its new CEO, Richard Král.

AbbVie Inc (ABBV.N) said on Thursday its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped the benefits of U.S. tax law changes.

AstraZeneca and Merck, known as MSD outside the U.S. and Canada, announced that the U.S. FDA has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).

The drug, verubecestat, was being tested in patients who showed only a glimmer of the symptoms that eventually rob them of memories and basic functions. It’s another setback in a long list of experimental treatments that have had little or no effect on the neurodegenerative disease.

UK gene cell therapy designer Oxford BioMedica’s shares jumped  as much as 11.2% to 12.30 pence this morning after announcing a $100 million collaboration and licence agreement with US hemophilia specialist Bioverativ , which last month agreed to be acquired by French pharma major Sanofi in a  $11.6 billion deal.

You do not get severe dengue from the vaccine. Just because you were administered with the vaccine means you’ll get infected. That’s s a little misinformation,” said Dr. Ruby Dizon, Sanofi Pasteur medical director.

Pfizer Inc. (NYSE:PFE) today announced its once-daily oral Janus kinase 1 (JAK1) inhibitor PF-04965842 received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with moderate-to-severe atopic dermatitis (AD).

The world's largest pharmaceutical manufacturing plant is now 98,500 square feet larger.And that expansion -- the most visible part of an ongoing $147 million investment by Pfizer Inc. -- is a very good thing for Portage and Kalamazoo County, local leaders say.

Pimco is the largest bond investor, but it also manages quite a bit in equities. According to S&P Capital IQ, Pimco now oversees $5.1 billion in U.S. equities.

Merck KGaA and Pfizer received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies.

Show more
Show less
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok